Company intelligence / Profile preview

Zhongzhi Pharmaceutical

Zhongshan, Guangdong Sheng, China

Ownership: Private
Employees: ~2643
Development stage: Other

Overview

Zhongzhi Pharmaceutical manufactures and sells a range of traditional Chinese medicines and herbal products. Its core commercial products include Cough Tablets ("克咳片"), Yinhuang Granules ("銀黃顆粒"), Yinqiao Detoxification Granules ("銀翹解毒顆粒"). The company also has at least one clinical-stage program for hyperuricemia with the Shuanghuang Tongfeng Capsule[5][10]. Revenue in 2022 was approximately RMB1.83 billion with continued growth post-pandemic due to increased demand for TCM.

Therapeutic areas: ImmunologyMetabolic DisordersInfectious Diseases
Modalities: Traditional Chinese medicine preparationsSmall moleculeHerbal medicines
Industry: Biotech

Partnerships

Invested in a US biotech firm to advance Alzheimer’s treatment as of December 2024; details not disclosed

Beyond the preview

Go deeper on Zhongzhi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhongzhi Pharmaceutical.

Explore the full profile